 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| LB4330 / L&L Biopharma, LB1410 / L&L Biopharma
Enrollment open, Combination therapy, Metastases: TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 9, 2024
P1/2, N=194, Recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
Not yet recruiting --> Recruiting
- |||| LB4330 / L&L Biopharma, LB1410 / L&L Biopharma
New P1/2 trial, Combination therapy, Metastases: TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 21, 2024
P1/2, N=194, Not yet recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
- Bis2 / L&L Biopharma
A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+T cells in patients with advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4693;
P1
Dose and efficacy expansion study is ongoing in more PDACs and other solid tumors. In the meantime, Phase I study of LB4330 in combination with PD1/TIM-3 bispecific antibody LB1410 has been initiated in different tumor types as well.
- || LB4330 / L&L Biopharma
Trial primary completion date, Metastases: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors?MEETCD8-001? (clinicaltrials.gov) - Mar 12, 2024
P1, N=66, Recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
In the meantime, Phase I study of LB4330 in combination with PD1/TIM-3 bispecific antibody LB1410 has been initiated in different tumor types as well. Trial primary completion date: Sep 2026 --> Sep 2025
- LB4330 / L&L Biopharma
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors. (On Demand | Hall A; Poster Bd # 504b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1320;
P1
Enrollment in cohort 1 began in Nov 2022. Clinical trial information: NCT05707676.
- ||| LB4330 / L&L Biopharma
New P1 trial, Metastases: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors?MEETCD8-001? (clinicaltrials.gov) - Feb 1, 2023
P1, N=66, Recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China